Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dirithromycin 500 mg vs Dynabac 250 mg
NCT02237768Phase 1Completed
- Sponsor
- Pharmaceutical Research Unit
- Start
- Dec 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dirithromycin in bacterial infection (3 arms), sponsored by Pharmaceutical Research Unit. Primary endpoints: Cmax Ratio at 120 hours and AUC Ratio at 120 hours. Started Dec 2014; status: completed.
02
Drugs
dirithromycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02237768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237768.